Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|17|31|3361-3369

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.17, Iss.31, 2018-02, pp. : 3361-3369

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of BACE1 Inhibitors for Alzheimer's Disease

By  

Current Medicinal Chemistry, Vol. 13, Iss. 15, 2006-06 ,pp. : 1811-1829

Bentham Science Publishers

Access to resources Recommend Favorite

GSK3 Inhibitors and Disease

By  

Mini Reviews in Medicinal Chemistry, Vol. 9, Iss. 9, 2009-08 ,pp. : 1024-1029

Bentham Science Publishers

Access to resources Recommend Favorite

GSK-3 inhibitors and their potential in the treatment of Alzheimer’s disease

By Kypta Robert M  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 10, 2005-10 ,pp. : 1315-1331

Informa Healthcare

Access to resources Recommend Favorite

Structure-Based &bgr;-Secretase (BACE1) Inhibitors

By  

Current Pharmaceutical Design, Vol. 20, Iss. 20, 2014-05 ,pp. : 3373-3379

Bentham Science Publishers

Access to resources Recommend Favorite

Approaches to a Multitargeting Drug Development: First Profiled 3- Ethoxycarbonyl-1-aza-9-oxafluorenes Representing a Perspective Compound Class Targeting Alzheimer Disease Relevant Kinases CDK1, CDK5 and GSK-3&bgr;

By  

Medicinal Chemistry, Vol. 10, Iss. 1, 2014-02 ,pp. : 90-97

Bentham Science Publishers

Access to resources Recommend Favorite